NCTID:NCT01816412||dmc_oversight:Yes||primary_outcome_count:1||primary_outcome_list:Composite of freedom from all-cause peri-operative (â‰¤30 day) death and freedom at 6 months from the following: index limb amputation (above or below the ankle), index limb re-intervention, and index-limb-related death.|6 months|,||||secondary_outcome_count:2||secondary_outcome_list:Safety|1, 3, 6, 12 and 24 months|,Efficacy|1, 3, 6, 12 and 24 months|,||||arm_group_count:2||arm_group_list:LDCB|Paclitaxel Coated Balloon,PTA|Standard Uncoated Balloon Angioplasty Catheter PTA Catheter,||||inclusion_exclusion: Inclusion Criteria: - Male or non-pregnant female â‰¥20 years of age; - Rutherford Clinical Category 2-4; - Length â‰¤15 cm; - â‰¥70% stenosis - Lesion location starts â‰¥1 cm below the common femoral bifurcation and terminates distally â‰¤2 cm below the tibial plateau AND â‰¥1 cm above the origin of the TP trunk; - A patent inflow artery as confirmed by angiography - At least one patent native outflow artery to the ankle Exclusion Criteria: - Life expectancy of < 2 years; - History of hemorrhagic stroke within 3 months; - Previous or planned surgical or interventional procedure within 2 weeks before or within 30 days after the index procedure; - History of MI, thrombolysis or angina within 2 weeks of enrollment; - Renal failure or chronic kidney disease - Severe calcification that renders the lesion un-dilatable ||mesh_term:Constriction, Pathologic,Paclitaxel,||||
NCTID:NCT02540018||dmc_oversight:No||primary_outcome_count:1||primary_outcome_list:Change in Late Lumen Loss (LLL)|at baseline and after 6 months|,||||secondary_outcome_count:8||secondary_outcome_list:Revascularisation of TVR|after 6 months and 12 months|,Revascularisation of TLR|after 6 months and 12 months|,Change in Rutherford classification|after 6 months and 12 months|,Change of ABI|after 6 months and 12 months|,Change of Life Quality|after 6 months and 12 months|,Absence of amputation|after 6 months and 12 months|,Bailouts|after 6 months and 12 months|,Mortality|after 6 months and 12 months|,||||arm_group_count:2||arm_group_list:Paclitaxel-coated LuminorÂ® Balloon Catheter|The balloon dilatation procedure, including deployment to the target lesion and balloon inflation, deflation and retrieval, is performed under fluoroscopic observation. An endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion is mandatory. After pre-dilatation of the target lesion an angiographic assessment will be performed (DSA or XA). Randomization will be performed by envelope pull. The treatment group represents the LuminorÂ® DEB PTA. After dilation of the target lesion, the PTA catheter is withdrawn through the introducer sheath, and a post-PTA angiography is performed (DSA or XA) to evaluate the technical result and possible procedural complications. A final run-off angiography (DSA or XA) of the BTK arteries is required.,Uncoated Balloon Catheter|Identical procedure also for control arm with PTA balloon (see below): After pre-dilatation, randomization will be performed by envelope pull. The control group requires an uncoated balloon catheter. After dilation of the target lesion, the PTA catheter is withdrawn and a post-PTA angiography is performed (DSA or XA) to evaluate the technical result and possible procedural complications. A final run-off angiography (DSA or XA) of the BTK arteries is required.,||||inclusion_exclusion: Inclusion Criteria: 1. Age â‰¥18 years 2. Subject must agree to undergo the 6-month angiographic and clinical follow-up (at 12 month post-procedure) 3. Peripheral vascular disease Rutherford class 2-4 4. De novo stenotic/re-stenotic lesion or occlusive lesions in the superficial femoral (SFA) and/or popliteal arteries (PA) 5. If the index lesion is re-stenotic, the prior PTA must have been >30 days prior to treatment in the current study 6. â‰¥70% diameter stenosis or occlusion 7. Target lesion length: â‰¤15 cm (TASC II A and B) 8. Only one lesion per limb and per patient can be treated (see definition chapter 6.5) 9. â‰¥ one patent intrapopliteal run-off artery to the foot of the index limb 10. Successful endoluminal guidewire passage through the target lesion 11. Predilatation prior to randomization 12. Life expectancy, in the investigators opinion of at least one year 13. Subject is able to verbally acknowledge and understand the aim of this trial and is willing and able to provide informed consent Exclusion Criteria: 1. Previous surgery in the target vessel 2. Major amputation in the same limb as the target lesion 3. Presence of aneurysm in the target vessel 4. Acute myocardial infarction within 30 days before intervention 5. Severely calcified target lesions in the SFA/PA resistant to PTA 6. Subjects requiring different treatment or raising serious safety concern regarding the procedure or the required medication 7. Women of childbearing potential expect women with the following criteria: - post-menopausal (12 month natural amenorrhea or 6 month amenorrhea with serum FSH > 40mlU/ml) - sterilization 86 weeks after bilateral ovariectomy with or without hysterectomy - using an effective method of birth control for the duration of the trial: implants, injectables, combined oral contraceptives, intrauterine device (in place for a period of at least 2 months prior to screening) and with negative serum pregnancy test - sexual abstinence - vasectomy partner 8. Pregnant and nursing women 9. Acute thrombus, stent or aneurysm in the index limb or vessel 10. Renal insufficiency with a serum creatinine >2.0 mg/dL at baseline 11. Platelet count <50 G/l or >600 G/l at baseline 12. Known hypersensitivity or contraindication to contrast agent that cannot be adequately preâ€medicated 13. Subjects with known allergies against Paclitaxel 14. Subjects with intolerance to antiplatelet, anticoagulant, or thrombolytic medications that would be administered during the trial 15. Dialysis or immunosuppressant therapy 16. Current participation (or within the last 3 months) in another interventional study ||mesh_term:Peripheral Arterial Disease,Peripheral Vascular Diseases,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT01083030||dmc_oversight:Yes||primary_outcome_count:1||primary_outcome_list:Late lumen loss|6 months|,||||secondary_outcome_count:1||secondary_outcome_list:Angiographic and clinical efficacy measures|6 months|,||||arm_group_count:2||arm_group_list:Conventional PTA|Angioplasty of SFA with uncoated balloon catheters,Drug coated balloon|Angioplasty of SFA with paclitaxel-coated balloon catheters,||||inclusion_exclusion: Inclusion Criteria: - Adult patients with PAOD, Rutherford stage 2-5, Occlusion or stenosis >70% in diameter of at least 3 cm length in the superficial femoral artery and/ or popliteal artery Exclusion Criteria: - Acute thrombus or aneurysm in the index limb/ vessel - Doubts in the willingness or capability of the patient to allow follow up examination ||mesh_term:Peripheral Arterial Disease,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT01850056||dmc_oversight:Yes||primary_outcome_count:1||primary_outcome_list:Late Lumen Loss|6 months|,||||secondary_outcome_count:7||secondary_outcome_list:Minimal lumen diameter (MLD)|6 months|,Restenosis rate of target vessel|6 months, 12 months, 18 months, 24months|,target lesion revascularization|6 months, 12 months, 18 months, 24 months|,change in Rutherford stage|6 months, 12 months, 18 months, 24 months|,change in ankle brachial index(ABI)|6 months|,major amputation|6 months, 12 months, 18 months, 24 months|,Death|12 months, 18 months, 24 months|,||||arm_group_count:2||arm_group_list:drug eluting balloon catheter|use drug eluting balloon catheter to inflate the stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery,common balloon catheter(uncoated drug)|use common balloon catheter to inflate stenosis or occlusion in SFA and/or popliteal artery,||||inclusion_exclusion: Inclusion Criteria: - Age between 18 and 80 years - Patients with peripheral artery disease (PAD), with Rutherford classification between 2 and 5 - an occlusion or a minimum grade of stenosisPrimary over 70% in the superficial femoral artery an /or the popliteal artery - Total length of treat lesion(s)is less or equal to 40cm - signed Patient informed consent form Exclusion Criteria: - plasma Cr level greater than 150 umol/L in patients - patients with acute thrombosis requiring lysis or thrombectomy - patient with a lysis or an lower limb intervention as a therapy within the last 6 weeks - patient requiring intervention in both lower limbs at the same time - target lesion can't be cross by the guide wire - distal outflow through less than one lower leg vessel - known hypersensitivity to aspirin, heparin, clopidogrel,paclitaxel, contrast medium, etc. - patients participating in another clinical trials with interfere with this trial in the past 3 months - pregnancy and lactating woman - untreatable bleeding diatheses - other diseases, such as cancer, liver disease, or cardiac insufficiency, which may lead to protocol violations or markedly shorten a patients's life expectancy(less than 2 years) - patients unable or unwilling to participate this trial ||mesh_term:Peripheral Arterial Disease,||||
NCTID:NCT01450722||dmc_oversight:Yes||primary_outcome_count:1||primary_outcome_list:Primary patency of the stent or graft at two year follow up|Ultrasound study at 2 years|,||||secondary_outcome_count:1||secondary_outcome_list:Amputation free survival|2 years|,||||arm_group_count:2||arm_group_list:drug eluting stent|Paclitaxel eluting stent for long superficial femoral artery obstruction,bypass operation|femoropopliteal artery bypass operation by using synthetic PTFE graft,||||inclusion_exclusion: Inclusion Criteria: - Patients suffering from severe life-style limiting claudication indicating revascularization as well as patients suffering from chronic critical ischemia and having de-novo SFA obstruction with total length of 7-20 cm will be recruited. - For claudicant patients an attempt of conservative treatment should be attempted before revacularization therapy. Both surgical bypass operation and endovascular treatment should be able to be safely performed; - the patient has not extensive additional cardio-pulmonary and/or cerebro-vascular diseases increasing remarkably operative risk. - At least one patent artery is to the ankle level. - The patient has given his/her informed consent. - Previous or simultaneus endovascular therapy of coexisting iliac disease is not a contraindication but study groups should be balanced. - Unplanned common femoral artery endarterectomy is not a contraindication when it is done at the same intervention to facilitate anastomosis creation. Exclusion Criteria: - Patients who have not given their written informed consent. - Patient has allergy for iodine contrast agent. - Patient is undergoing hemodialysis. - Patient has undergone previous endovascular treatment for the target lesion (restenotic lesions). - Patient has also infrapopliteal disease indicating revascularization. - Patient is pregnant ||mesh_term:Intermittent Claudication,Ischemia,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT00156624||dmc_oversight:n/a||primary_outcome_count:1||primary_outcome_list:Late lumen loss of vessel segment following dilatation after 6 months||,||||secondary_outcome_count:2||secondary_outcome_list:Thrombotic complications or revascularization of the target vessel, death; adverse reactions known to occur after paclitaxel (high dose tumor therapy except reactions to the detergent)||,Paclitaxel plasma concentration will be determined immediately after administration||,||||arm_group_count:0||arm_group_list:||||inclusion_exclusion: Inclusion Criteria: - Adults - Chronic Occlusions and stenosis (history at least 6 weeks) â‰¥70 % diameter Stenosis > 2cm in the arteria femoralis superficialis or arteria poplitea - Various criteria assuring ethical issues and follow up Exclusion Criteria: - Conditions requiring different treatment or raising serious safety concern regarding the procedure or the required medication. - Pregnancy can not be excluded - Doubts in the willingness or capability of the patient to allow 6 months follow up ||mesh_term:Arterial Occlusive Diseases,||||
NCTID:NCT00120406||dmc_oversight:Yes||primary_outcome_count:2||primary_outcome_list:Event-free Survival Rate|12 months|,Primary Patency|12 months|,||||secondary_outcome_count:0||secondary_outcome_list:||||arm_group_count:2||arm_group_list:1|ZilverÂ® PTXâ„¢ Drug Eluting Vascular Stent,2|Angioplasty,||||inclusion_exclusion: Inclusion Criteria: - Patient has signed and dated the informed consent. - Patient has up to 2 documented stenotic or occluded atherosclerotic lesions (up ro 14 cm long) of the above-the-knee femoropopliteal artery, up to one in each limb, that meet all of the inclusion criteria and none of the exclusion criteria. - Patient has a de novo or restenotic lesion(s) with >50% stenosis documented angiographically and no prior stent in the target lesion. - Patient has symptoms of peripheral arterial disease classified as Rutherford Category 2 or greater. - Patient has a resting Ankle Brachial Index (ABI) <0.9 or an abnormal exercise ABI if resting ABI is normal. Patient with incompressible arteries (ABI >1.2) must have a Toe Brachial Index (TBI) <0.8. - Patient agrees to return for a clinical status assessment and duplex ultrasound at 6 months, 12 months, and at 2, 3, 4, and 5 years. - Patient agrees to return for x-rays at 6 and 12 months. - Patient agrees to return for angiography at 12 months. - Patient agrees to be contacted by telephone at 1, 3, 9, and 18 months to assess clinical status. Exclusion Criteria: - Patient is pregnant or breast-feeding. - Patient is simultaneously participating in another investigational drug or device study. - Patient has significant stenosis or occlusion of inflow tract not successfully treated before this procedure. - Patient has any planned surgical or interventional procedure within 30 days after the study procedure. - Patient has had previous stenting of target vessel. - Patient in whom antiplatelet and/or anticoagulant therapy is contraindicated. - Patient has known hypersensitivity or contraindication to aspirin, antiplatelet medication, contrast dye, paclitaxel or nitinol and, in the opinion of the investigator, cannot be adequately premedicated. - Patient lacks at least one patent vessel of runoff with <50% stenosis throughout its course. - Patient has untreated angiographically-evident thrombus in the target lesion. [Additional criteria may apply.] ||mesh_term:Vascular Diseases,Peripheral Vascular Diseases,Peripheral Arterial Disease,||||
NCTID:NCT03023098||dmc_oversight:No||primary_outcome_count:2||primary_outcome_list:TLR (Target lesion revascularization)|12 months|,Graft occlusion|0-12 months|,||||secondary_outcome_count:2||secondary_outcome_list:Major amputation|0-12 months|,Death|0-12 months|,||||arm_group_count:2||arm_group_list:Drug-eluting balloon|,Conventional PTA|,||||inclusion_exclusion: Inclusion Criteria: - Any venous bypass with stenosis warranting intervention Exclusion Criteria: - Previous PTA with drug-eluting balloon, thrombolysis, coagulopathy ||mesh_term:Constriction, Pathologic,||||
